市场调查报告书

全球非类鸦片物质止痛贴片市场:各贴片类型、通路、地区(2018年~2023年)

Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 704955
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
全球非类鸦片物质止痛贴片市场:各贴片类型、通路、地区(2018年~2023年) Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

全球非类鸦片物质止痛贴片市场,预计从2018年到2023年的整个预测期内以3.5%的年复合成长率发展。

本报告提供全球非类鸦片物质止痛贴片市场调查,市场概要,各贴片类型、通路、地区的市场规模的变化与预测,市场趋势,市场成长要素及阻碍因素分析,市场机会,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 简介

  • 市场定义

第2章 调查方法

第3章 摘要整理

第4章 主要影响要素

第5章 市场概要

  • 目前市场方案
  • 波特的五力分析
    • 买方议价能力
    • 供给企业谈判力
    • 新加入业者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关系

第6章 市场动态

  • 成长要素
    • 疼痛相关疾病的疾病负担的上升
    • 疼痛管理治疗的研究开发的增加
    • 类鸦片物质药的副作用的认识提高
  • 阻碍因素
    • 替代疗法的存在
    • 贴片的黏合性的问题和认知度低
  • 市场机会
  • 主要课题

第7章 市场区隔

  • 贴片各类型
    • 辣椒素贴片
    • 双氯芬酸贴片
    • 酮洛芬贴片
    • 利多卡因贴片
    • 水杨酸甲基贴片
    • 其他
  • 各销售管道
    • 医院药局
    • 零售药局
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第8章 竞争情形

  • M&A分析
  • 协定,合作,伙伴关系
  • 新产品的销售

第9章 主要企业

  • Acorda Therapeutics, Inc.
  • Allergan
  • Endo Pharmaceuticals PLC
  • GlaxoSmithKline PLC
  • 久光制药
  • IBSA Institut Biochimque SA
  • Mylan NV
  • Pfizer, Inc
  • TEH SENG Pharmaceutical Mfg. Co., Ltd.
  • 帝国制药

第10章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 64062

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths. Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting among other ways, an underlying disease like pancreatitis, spine disease, arthritis, and autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. As per, CDC around 43% of the population suffer from pain on some days and around 20% of the population suffer from pain every day or on most days. There are numerous risk factors for chronic pain. Non-opioid patches are more preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches and also the drugs is released over a long period of time, therefore, helping in managing the pain for a longer duration and considered as a valuable driver for this market.

However, availability of alternative treatments and low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of non-opioid pain patch market.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Based on type, the market is segmented into lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches are considered as the most commonly available patch for the treatment of chronic and acute pain. According to the American Academy of Pain Medicine (AAPM), chronic pain affects approximately 1.5 billion people worldwide with prevalence increasing with age. The proportion of the world's population over 60 years will nearly double from 12% to 22%, between 2015 and 2050, as per WHO estimates. Lidocaine patches are recommended as first-line therapy for the treatment of neuropathic pain in older patients, which is expected to boost the market growth. Furthermore, the increasing burden of diseases, along with safety profile and efficacy associated with lidocaine patches are expected to drive the market growth during the forecast period.

North America is Expected to Dominate the Non-opioid Pain Patch Market

North America is expected to retain its dominance in this market. chronic pain is one of the primary factors responsible for the growth of the market. According to the National Institute of Health (NIH), in 2016, around 20% of US adults were suffering from chronic pain and 8% had high impact, which at least limits one major life activity in the patient. In addition, the countries in North America are increasingly facing scrutiny on the opioid crises issue, from the government authorities, which in turn are expected to benefit the rise of non-opioid alternatives. Thus, rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the non-opioid pain patch market are - Clarion Brands Inc., Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), TEH SENG Pharmaceutical, Teikoku Seiyaku, Teva Pharmaceuticals, and Veridian Healthcare.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Pain-Related Disorders
    • 4.2.2 Rising R&D in Pain Management Treatments
    • 4.2.3 Benefits Associated with Non-opioid Pain Patches over Conventional Medications
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Low Adoption Rate of Non-opioid Pain Patch due to Unawareness
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Patch Type
    • 5.1.1 Lidocaine Patches
    • 5.1.2 Diclofenac Patches
    • 5.1.3 Capsaicin Patches
    • 5.1.4 Ketoprofen Patches
    • 5.1.5 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clarion Brands Inc.
    • 6.1.2 Endo Pharmaceuticals Inc.
    • 6.1.3 Hisamitsu Pharmaceutical Co. Inc.
    • 6.1.4 Sanofi S.A.
    • 6.1.5 Sorrento Therapeutics (SCILEX Pharmaceuticals)
    • 6.1.6 TEH SENG Pharmaceutical Mfg Co
    • 6.1.7 Teikoku Seiyaku Co. Ltd.
    • 6.1.8 Teva Pharmaceuticals Industries Ltd.
    • 6.1.9 Veridian Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top